Skip to main content
. 2023 Jul 31;14:1221723. doi: 10.3389/fendo.2023.1221723

Figure 4.

Figure 4

Survival rate one year (A) and remission rate (B) after ICI administration by gender according to the presence or absence of thyroid-related irAEs. Frequency of thyroid disorders by sex (C). Gender difference in 1-year survival with and without thyroid-related irAEs for each ICI; ipilimumab and PD-1 inhibitors (D), PD-1 inhibitors (E), and PD-L1 inhibitors (F).